In contrast to single‐voxel MRS, MRSI is sensitive to diffuse and potentially heterogeneous changes in brain metabolites. Advances in MRI hardware have encouraged the development of advanced spectroscopic techniques (magnetic resonance spectroscopic imaging ) to measure neurochemical distributions at increasingly high spatial resolutions. The highly localized nature of this acquisition sharply contrasts with the ubiquitous presence of metabolites across the entire brain. Magnetic resonance spectroscopy (MRS) is a technique that is used to acquire in vivo brain tissue metabolite signals from single, rather large, preselected volumes that typically occupy as much as 8 cm 3.

We report average metabolite values including glutamate + glutamine (Glx), glycerophosphocholine, choline and phosphocholine (tCho), (phospo)creatine, myo‐inositol and glycine (mI‐Gly), glutathione, N‐acetyl‐aspartyl glutamate(and glutamine), and N‐acetyl‐aspartate in the basal ganglia, central WM (thalamic radiation, corpus callosum) as well as insular cortex and intracalcarine sulcus.

Partial‐volume correction improved the delineation of deep brain nuclei. Implementation of automatic quality control thresholds and normalization of metabolic maps from 23 subjects to the Montreal Neurological Institute (MNI) standard atlas facilitated the creation of high‐resolution average metabolite maps of several clinically relevant metabolites in central brain regions, while accounting for macromolecular distributions. Anatomical images were used to perform high‐resolution (1 mm 3) partial‐volume correction to account for gray matter, white matter (WM), and cerebral‐spinal fluid signal contributions. The aim of this work was to address some of these factors and to develop an acquisition, reconstruction, and postprocessing pipeline to derive lipid‐suppressed metabolite values of central brain structures based on free‐induction decay measurements made using a 7 T MR scanner.

Optibet shell function